333 related articles for article (PubMed ID: 1683338)
1. [Zotepine: treatment of schizophrenic patients with predominantly negative symptoms. A double-blind study vs. haloperidol].
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():36-40. PubMed ID: 1683338
[TBL] [Abstract][Full Text] [Related]
2. [Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind study].
Fleischhacker WW; Barnas C; Stuppäck CH; Sperner-Unterweger B; Miller C; Hinterhuber H
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():10-3. PubMed ID: 1683332
[TBL] [Abstract][Full Text] [Related]
3. Zotepine in the treatment of schizophrenic patients with prevailingly negative symptoms. A double-blind trial vs. haloperidol.
Barnas C; Stuppäck CH; Miller C; Haring C; Sperner-Unterweger B; Fleischhacker WW
Int Clin Psychopharmacol; 1992; 7(1):23-7. PubMed ID: 1352521
[TBL] [Abstract][Full Text] [Related]
4. A comparison of an atypical and typical antipsychotic, zotepine versus haloperidol in patients with acute exacerbation of schizophrenia: a parallel-group double-blind trial.
Petit M; Raniwalla J; Tweed J; Leutenegger E; Dollfus S; Kelly F
Psychopharmacol Bull; 1996; 32(1):81-7. PubMed ID: 8927680
[TBL] [Abstract][Full Text] [Related]
5. [Double-blind comparison of 3 x 75 mg zotepine und 3 x 4 mg haloperidol in acute schizophrenic patients].
Klieser E; Lehmann E; Tegeler J
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():14-7. PubMed ID: 1683333
[TBL] [Abstract][Full Text] [Related]
6. Zotepine versus placebo in the treatment of schizophrenic patients with stable primary negative symptoms: a randomized double-blind multicenter trial.
Möller HJ; Riedel M; Müller N; Fischer W; Kohnen R
Pharmacopsychiatry; 2004 Nov; 37(6):270-8. PubMed ID: 15551193
[TBL] [Abstract][Full Text] [Related]
7. Zotepine in the treatment of negative symptoms in chronic schizophrenia.
Fleischhacker WW; Barnas C; Stuppäck C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):58-60. PubMed ID: 2883684
[TBL] [Abstract][Full Text] [Related]
8. Zotepine, a neuroleptic drug with a bipolar therapeutic profile.
Dieterle DM; Ackenheil M; Müller-Spahn F; Kapfhammer HP
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):52-7. PubMed ID: 2883683
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of zotepine for the treatment of Taiwanese schizophrenic patients: a double-blind comparison with haloperidol.
Hwang TJ; Lin SK; Lin HN
J Formos Med Assoc; 2001 Dec; 100(12):811-6. PubMed ID: 11802520
[TBL] [Abstract][Full Text] [Related]
10. [Effectiveness and tolerance of zotepine in a double-blind comparison with perazine in schizophrenic patients].
Dieterle DM; Müller-Spahn F; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():18-22. PubMed ID: 1683334
[TBL] [Abstract][Full Text] [Related]
11. Comparison of efficacy of zotepine and thiothixene in schizophrenia in a double-blind study.
Sarai K; Okada M
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):38-46. PubMed ID: 2883680
[TBL] [Abstract][Full Text] [Related]
12. [Clinical effectiveness of zotepine in treatment of negative schizophrenic symptoms. Results of an open and a double-blind controlled trial].
Müller-Spahn F; Dieterle D; Ackenheil M
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():30-5. PubMed ID: 1683337
[TBL] [Abstract][Full Text] [Related]
13. A placebo-controlled comparison of zotepine versus chlorpromazine in patients with acute exacerbation of schizophrenia.
Cooper SJ; Tweed J; Raniwalla J; Butler A; Welch C
Acta Psychiatr Scand; 2000 Mar; 101(3):218-25. PubMed ID: 10721870
[TBL] [Abstract][Full Text] [Related]
14. [Effectiveness of zotepine in therapy-refractory psychoses. An open, multicenter study in eight psychiatric clinics].
Harada T; Otsuki S; Fujiwara Y
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():41-4. PubMed ID: 1683339
[TBL] [Abstract][Full Text] [Related]
15. [Zotepine versus perazine in patients with paranoid schizophrenia: a double-blind controlled trial of its effectiveness].
Wetzel H; von Bardeleben U; Holsboer F; Benkert O
Fortschr Neurol Psychiatr; 1991 Sep; 59 Suppl 1():23-9. PubMed ID: 1683336
[TBL] [Abstract][Full Text] [Related]
16. Low-dose zotepine in the maintenance treatment of schizophrenia.
Fleischhacker WW; Stuppäck C; Barnas C; Unterweger B; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):61-3. PubMed ID: 2883685
[TBL] [Abstract][Full Text] [Related]
17. A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients.
Chouinard G; Jones B; Remington G; Bloom D; Addington D; MacEwan GW; Labelle A; Beauclair L; Arnott W
J Clin Psychopharmacol; 1993 Feb; 13(1):25-40. PubMed ID: 7683702
[TBL] [Abstract][Full Text] [Related]
18. Results of an open phase II study with zotepine--a new neuroleptic compound.
Fleischhacker WW; Unterweger B; Barnas C; Stuppäck C; Hinterhuber H
Pharmacopsychiatry; 1987 Feb; 20(1 Spec No):64-6. PubMed ID: 2883686
[TBL] [Abstract][Full Text] [Related]
19. Zotepine vs. haloperidol in paranoid schizophrenia: a double-blind trial.
Fleischhacker WW; Barnas C; Stuppäck CH; Unterweger B; Miller C; Hinterhuber H
Psychopharmacol Bull; 1989; 25(1):97-100. PubMed ID: 2570438
[No Abstract] [Full Text] [Related]
20. A double-blind controlled study of intramuscular zuclopenthixol acetate and liquid oral haloperidol in the treatment of schizophrenic patients with acute exacerbation.
Chouinard G; Safadi G; Beauclair L
J Clin Psychopharmacol; 1994 Dec; 14(6):377-84. PubMed ID: 7884017
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]